A newly developed screening technology may be useful for identifying potential targets for drugs against dengue fever, an infectious disease that lacks effective prevention or treatment countermeasures (Chu JJ and Yang PL. Proc Natl Acad Sci U S A. 2007;104:3520-3525).
Using this microscopy-based immunofluorescence technology, investigators at Harvard Medical School, in Boston, discovered that inhibitors of the c-Src protein kinase hinder the mosquito-borne flavivirus that causes dengue fever. Further analysis revealed that the anticancer drug dasatinib, a c-Src protein kinase inhibitor, prevents the assembly of dengue virions and may therefore be an effective therapy.
Hampton T. Dengue Drug Screen. JAMA. 2007;297(13):1423. doi:10.1001/jama.297.13.1423-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: